-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FSQfhdxOiHU2n4JfmTa2aq2k10BcNeZHmEPipKvuXnetDp6lKc9x4u+irQjAJcMt uIEbd8gMo7/L3SGBl6FWxg== 0000950134-02-007556.txt : 20020624 0000950134-02-007556.hdr.sgml : 20020624 20020624172743 ACCESSION NUMBER: 0000950134-02-007556 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020624 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SURMODICS INC CENTRAL INDEX KEY: 0000924717 STANDARD INDUSTRIAL CLASSIFICATION: ADHESIVES & SEALANTS [2891] IRS NUMBER: 411356149 STATE OF INCORPORATION: MN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23837 FILM NUMBER: 02685799 BUSINESS ADDRESS: STREET 1: 9924 W 74TH ST CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 BUSINESS PHONE: 6128292700 MAIL ADDRESS: STREET 1: 9924 WEST 74TH ST CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 FORMER COMPANY: FORMER CONFORMED NAME: BSI CORP DATE OF NAME CHANGE: 19970506 8-K 1 c70349e8vk.htm FORM 8-K SurModics, Inc.
Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2002

SurModics, Inc.
(Exact name of Registrant as Specified in its Charter)

Minnesota
(State or Other Jurisdiction of Incorporation)

     
0-23837
(Commission File Number)		   41-1356149
(IRS Employer
Identification No.)

9924 West 74th Street
Eden Prairie, Minnesota 55344
(Address of Principal Executive Offices and Zip Code)

(952) 824-2700
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Item 5. Other Events
Item 7. Financial Statements and Exhibits
SIGNATURES
EXHIBIT INDEX
EX-99 Press Release

Table of Contents

Item 5. Other Events

     On June 24, 2002, the Registrant issued a press release relating to third quarter earnings. The full text of the press release is set forth in Exhibit 99 which is attached hereto and incorporated in this Report as if fully set forth herein.

Item 7. Financial Statements and Exhibits

     
Exhibit 99   Press release dated June 24, 2002.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

             
        SURMODICS, INC.
 
Date:   June 24, 2002   By:   /s/ Stephen C. Hathaway
Stephen C. Hathaway
Vice President and CFO

 

Table of Contents

EXHIBIT INDEX

SurModics, Inc.
Form 8-K Current Report

 

     
Exhibit Number   Description
 
99   Press release dated June 24, 2002

  EX-99 3 c70349exv99.htm EX-99 PRESS RELEASE SurModics, Inc.

 

Exhibit 99

Contact:
Stephen C. Hathaway
Vice President & CFO
(952) 829-2700

FOR IMMEDIATE RELEASE

SurModics Reaffirms It Will Meet Revenue and Earnings Targets for the Fiscal Third Quarter

     EDEN PRAIRIE, Minnesota — June 24, 2002 — SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification solutions to medical device manufacturers, said today that it expects revenue in the range of $7.4 to $7.7 million and earnings of $.10 to $.11 per share for the third quarter ending June 30, 2002. The consensus analysts’ estimate for revenue is $7.0 million, and the earnings consensus is $.10 per share.

     Dale Olseth, Chairman and CEO, said; “Due to the unusual activity in our stock over the past several days, we are taking this opportunity to reaffirm guidance for the June quarter. We continue to see strong demand for our coating business, as shown by the expected revenue increase of at least 33 percent in the fiscal third quarter. This is on top of the 31 percent gain in the fiscal second quarter.

     “These results do not contain any royalties from the sales of drug-coated stents by Johnson & Johnson. As with all our clients with coated products on the market, royalties are calculated based on actual product sales, and are generally paid 45 days after the end of each quarter. Based on J&J’s European market launch in April, we expect to receive the first royalties associated with the sales of drug-coated stents in our fiscal fourth quarter ending September 30, 2002,” Olseth added.

     SurModics intends to release its actual financial results for the quarter ending June 30, 2002, at the market close on Tuesday, July 16, 2002.

     SurModics, Inc., a leading provider of surface modification solutions, licenses its patented photoactivated coating processes to medical device manufacturers around the world. A significant portion of SurModics’ revenue is generated through royalties on the sale of coated products. SurModics’ Internet address is www.surmodics.com.

Forward-Looking Statements

     Certain statements contained in this press release are considered “forward-looking statements” which provide current expectations or forecasts of future events, including SurModics’ expectations regarding the revenue and earnings for its fiscal third quarter and the

 

 

expected receipt of royalty payments from the J&J agreement. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Such statements involve a variety of risks and uncertainties, known and unknown, that could cause actual results to differ from those anticipated by the forward-looking statements made in this release. As we complete the third fiscal quarter and prepare final quarterly financial statements, information not previously known may come to our attention that requires an adjustment in the financial results we have estimated in this release. Other general business and economic factors identified from time to time in our filings with the Securities and Exchange Commission may also affect the actual results. Investors are advised to consult any further disclosures by SurModics on this subject in its filings with the Securities and Exchange Commission.

# # #

  -----END PRIVACY-ENHANCED MESSAGE-----